Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship...
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. In particular, the stock is overpriced on P/E.
Target Price
The average target price of NEO is 14 and suggests 73% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell